Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:40:25 EDT Wed 15 May 2024
Enter Symbol
or Name
USA
CA



News for U:MRNA from 2023-05-16 to 2024-05-15 - 68 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-13 07:02U:MRNANews ReleaseModerna to Present at Upcoming Conferences in May/June 2024
2024-05-10 07:22U:MRNANews ReleaseModerna Announces Update on Investigational RSV Vaccine
2024-05-08 08:30U:MRNANews ReleaseMitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
2024-05-02 06:34U:MRNANews ReleaseModerna Reports First Quarter 2024 Financial Results and Provides Business Updates
2024-04-25 07:02U:MRNANews ReleaseModerna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
2024-04-24 08:45U:MRNANews ReleaseModerna and OpenAI Collaborate To Advance mRNA Medicine
2024-04-22 07:04U:MRNANews ReleaseModerna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
2024-04-17 07:02U:MRNANews ReleaseModerna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
2024-04-03 11:05U:MRNANews ReleasePhase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
2024-03-27 06:32U:MRNANews ReleaseModerna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
2024-03-26 07:03U:MRNANews ReleaseModerna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
2024-02-29 07:03U:MRNANews ReleaseModerna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
2024-02-28 07:02U:MRNANews ReleaseModerna to Present at Upcoming Investor Conferences in March 2024
2024-02-22 06:42U:MRNANews ReleaseModerna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
2024-02-22 06:41U:MRNANews ReleaseModerna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
2024-02-07 09:15U:MRNANews ReleaseModerna Chief Executive Officer St ƒ ©phane Bancel Elected to National Academy of Engineering
2024-02-01 07:02U:MRNANews ReleaseModerna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
2024-01-31 17:46U:MRNANews ReleaseModerna Named to Fortune's List of World's Most Admired Companies
2024-01-08 07:03U:MRNANews ReleaseModerna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 16:08U:MRNANews ReleaseModerna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-15 08:01U:MRNANews ReleaseModerna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company ¢ € ™s Investigational Respiratory Syncytial Virus (RSV) Vaccine
2023-12-14 07:00U:MRNANews ReleaseFirst In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
2023-12-14 06:32U:MRNANews ReleaseModerna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
2023-12-12 08:01U:MRNANews ReleaseModerna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
2023-12-11 06:45U:MRNANews ReleaseMerck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA ‚ ® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
2023-12-07 07:01U:MRNANews ReleaseModerna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
2023-11-21 06:00U:MRNANews ReleaseFlagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
2023-11-14 07:01U:MRNANews ReleaseModerna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
2023-11-08 16:18U:MRNANews ReleaseModerna to Present at Upcoming Conferences in November 2023
2023-11-08 07:02U:MRNANews ReleaseModerna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
2023-11-07 08:01U:MRNANews ReleaseModerna Tops BioSpace ¢ € ™s Best Places to Work Ranking for Third Consecutive Year
2023-11-02 06:32U:MRNANews ReleaseModerna Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-11-01 10:30U:MRNANews ReleaseFlagship Pioneering Launches Pioneering Intelligence
2023-10-30 08:19U:MRNANews ReleaseCEPI y Moderna aprovechan la tecnolog ƒ ­a ARNm para avanzar en la Misi ƒ ³n de los 100 d ƒ ­as
2023-10-30 08:14U:MRNANews ReleaseCEPI und Moderna nutzen mRNA-Technologie zur Weiterentwicklung der ¢ € ž100 Days Mission ¢ € œ
2023-10-30 03:03U:MRNANews ReleaseCEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
2023-10-26 14:51U:MRNANews ReleaseModerna Named a Top Employer by Science for Ninth Consecutive Year
2023-10-24 07:01U:MRNANews ReleaseModerna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
2023-10-24 06:30U:MRNANews ReleaseCaris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
2023-10-19 07:41U:MRNANews ReleaseModerna to Host Second Digital Investor Event on November 8th, 2023
2023-10-12 07:01U:MRNANews ReleaseModerna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
2023-10-04 07:02U:MRNANews ReleaseModerna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
2023-09-29 19:40U:MRNANews ReleaseModerna Recommends Shareholders Reject Amended ¢ € œMini-Tender ¢ €  Offer by TRC Capital Investment Corporation
2023-09-14 10:18U:MRNANews ReleaseEMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna ¢ € ™s Updated Covid-19 Vaccine in The European Union
2023-09-13 06:32U:MRNANews ReleaseModerna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
2023-09-11 14:01U:MRNANews ReleaseModerna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
2023-09-11 07:02U:MRNANews ReleaseModerna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
2023-09-11 06:30U:MRNANews ReleaseFlagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
2023-09-08 16:38U:MRNANews ReleaseModerna Recommends Shareholders Reject ¢ € œMini-Tender ¢ €  Offer by TRC Capital Investment Corporation
2023-09-06 16:33U:MRNANews ReleaseModerna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
2023-09-06 09:06U:MRNANews ReleaseModerna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
2023-09-06 07:02U:MRNANews ReleaseModerna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
2023-08-30 07:01U:MRNANews ReleaseModerna to Host ‚  Investor Event - R&D Day and Business Updates
2023-08-29 09:00U:MRNANews ReleaseInvaio achieves first registration for citrus greening solution featuring Trecise ¢ „ ¢ technology
2023-08-17 16:16U:MRNANews ReleaseModerna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
2023-08-14 10:00U:MRNANews ReleaseUMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings
2023-08-03 06:30U:MRNANews ReleaseModerna Reports Second Quarter 2023 Financial Results and Provides Business Updates
2023-07-26 06:45U:MRNANews ReleaseMerck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA ‚ ® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
2023-07-13 07:01U:MRNANews ReleaseModerna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
2023-07-05 07:01U:MRNANews ReleaseModerna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
2023-07-03 01:00U:MRNANews ReleaseModerna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
2023-06-29 13:34U:MRNANews ReleaseMODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
2023-06-22 16:05U:MRNANews ReleaseModerna Files for FDA Authorization of Its Updated COVID-19 Vaccine
2023-06-05 08:01U:MRNANews ReleaseModerna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
2023-06-01 16:05U:MRNANews ReleaseModerna to Present at Upcoming Conferences in June 2023
2023-05-30 08:01U:MRNANews ReleaseModerna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
2023-05-19 07:01U:MRNANews ReleasePhase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
2023-05-16 06:00U:MRNANews ReleaseFlagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry